Modern Slavery Act (Cth)

Roche fully endorses the Modern Slavery Act 2018 (Cth) (the Act) and supports the abolition of human trafficking, slavery, servitude, forced labour, forced marriage, child labour, deceptive recruiting and debt bondage. Roche acknowledges the importance of companies working together to tackle such issues in our society and around the world. Roche condemns all forms of Modern Slavery. Staff and business partners are requested to speak up and report incidents if they believe that someone has done, is doing, or may be about to do something that violates this principle.

For more than 120 years, both in our own operations and in our value chain, Roche has fostered the protection of Human Rights. As part of our commitment to sustainability, we are continuously making impactful and positive contributions in areas that are within our sphere of influence.

Therequired to be included in every Roche contract, incorporates the five auditable key principles of the Pharmaceutical Supply Chain Initiative (PSCI):

  • Ethics: suppliers must conduct their business in an ethical manner and act with integrity

  • Labour: suppliers must be committed to uphold the human rights of workers and to treat them with dignity and respect

  • Health and Safety: suppliers must provide a safe and healthy working environment, including for any company-provided living quarters

  • Environment: suppliers must operate in an environmentally responsible and efficient manner, and they must minimise adverse impacts on the environment

  • Management Systems: suppliers must use management systems to facilitate continual improvement and compliance with the expectations of these principles

We have a formal process and methodology for assessing our suppliers in order to identify those at higher risk for Human Rights violations. This Human Rights risk assessment is embedded in our standardised due diligence process conducted before engaging new suppliers. It is used to identify suppliers for inclusion in our(SSAV) program, through which we directly evaluate supplier Human Rights compliance.

Each Roche Australia entity is a proprietary limited company registered under the Corporations Act 2001 (Cth).

They are the Australian sales affiliates of a global group of companies whose function is to import, distribute and sell the group’s medicines, assays, diagnostic equipment, and other health care products to customers in the Australian healthcare market. These products are acquired from other Roche group companies offshore and selected third-party suppliers, and imported into Australia by each Australian affiliate (Fig.1).

Other suppliers support this primary activity through the provision of local goods and services such as facilities support, distribution and warehousing, marketing, and specialised professional services. A small proportion of diagnostics products are acquired locally.

In mapping risk for each part of the supply chain, Roche considers how it could directly cause or contribute to Modern Slavery or be directly linked to Modern Slavery through the actions of a third party in its supply chain.

Risk of causing or contributing to modern slavery practices

The risk of Roche’s operations causing or contributing to modern slavery practices is assessed as low.

As far as causing modern slavery practices is concerned, Roche strives to comply fully with the letter of all workplace and industrial relations laws, regulations and awards with regard to all employees and contractors on its staff. Roche operates in a very competitive environment for recruitment, and offers generous terms and conditions to staff in order to position itself as an employer of choice in the industry.

In terms of contributing to modern slavery practices, Roche’s criteria for selecting business partners is not based primarily on cost criteria, but rather on cultural fit, reputation and quality considerations. The protection, and indeed enhancement of Roche’s own global reputation for integrity, innovation, reliability and quality is front of mind in all projects where business partners are involved. Roche’s approach to managing these important relationships is to work with its business partners rather than setting unrealistic cost targets and delivery timeframes for them to meet.

Global Supply Chain

The primary provider of goods and services is the Roche Group, a founding member of the PSCI with established processes and protocols for identifying and minimising Modern Slavery risk within the supply chain.

Local Supply Chain

With no local manufacturing operations and the majority of products sourced from Roche Group, the risk of Modern Slavery within the product supply chain is considered to be low. Where risk can manifest within the direct control of the Australian business is in the local sourcing of products and services. Examples include:

  • Production of materials such as packaging and medical equipment sourced by third party partners in the execution of medical or distribution services.

  • Services that are sourced locally including digital design and software as a service, plus specialised services such as device calibration and water purification services.

  • The engagement of labour in the delivery of transport and logistics, serviced facilities, catering, event management and clinical trials.

  • Internal recruitment and management of staff.

The risk is assessed taking into account the impact from both a commercial and from a community point of view. While the potential impacts are considered to be serious, the likelihood of Roche causing or contributing to modern slavery is considered to be low.

Looking forward 2022 Human Rights risks

Risk of being directly linked to modern slavery practices

At Roche we recognise that there is a risk for us to be directly linked to Modern Slavery when we are purchasing goods and services from third parties. We continue to focus on the topic of Modern Slavery within our Australian business operations, including during our due diligence of new suppliers, ensuring that their ethics and approach to Modern Slavery is included as part of our onboarding activities.

Global Supply Chain

Roche conducts risk-based due diligence on potential and existing suppliers and business partners. We hold our suppliers to high performance expectations that are aligned with our own values and principles. These are detailed in thethat is referenced in every Roche contract. In order to enhance transparency within our sphere of influence, we also expect suppliers and business partners to actively assess and manage Human Rights risks in their own business partners.

Local Supply Chain

While reliance can be placed on the diligence of global practices to manage the larger network, similar practices and principles have been adopted at a local level. Locally, suppliers are allocated across 15 categories with each assessed using 4 key risk indicators derived from government guidance and Roche global good practice.

This good practice includes recommendations published by the PSCI and is complemented by reporting from the World Economic Forum (WEF), the Organisation for Economic Co-operation & Development (OECD), and The Global Slavery Index. The 4 drivers are:

  • Sector and industry risks

    Certain sectors and industries may have higher modern slavery risks because of their characteristics, products and processes.

  • Products and services risks

    Certain products and services may have higher modern slavery risks because of the way they are produced, provided or used.

  • Geographic risks

    Some countries may have higher risks of modern slavery, due to poor governance, weak rule of law, conflict, migration flows and socioeconomic factors like poverty.

  • Entity risks

    Some entities may have particular modern slavery risks because of poor governance structures, or a track record of treating workers poorly or of human rights violations.

Suppliers are mapped to an assessment matrix by category and further stratified based on utilisation levels. Further review is carried out by procurement specialists to identify higher risk individual suppliers and a corresponding response plan enacted:

  • Higher Risk: dedicated relationship manager with oversight and validation of supplier responses.

  • Medium Risk: oversight with periodic review and validation where appropriate.

  • Lower Risk: annual review supported by supplier surveys and industry due diligence.

a) Due Diligence and Assurance Visits

Suppliers are surveyed with regard to their businesses, their position on the Act and how they intend to eliminate Modern Slavery within their business and their own supply chains.

Depending on the responses received, suppliers are followed up through dedicated supplier relationship management activity or through assurance visits to supplier premises. All contracts with suppliers contain a commitment from the supplier to uphold anti-slavery laws, in the same way that they agree to observe anti-bribery and anti-corruption laws.

There were no local findings resulting from our assurance activities during 2021.

b) Staff Training

Staff at Roche are trained on the Roche Code of Conduct and Roche Behaviours in Business (RoBiB) policies which cover the topic of Modern Slavery. We continue to provide targeted training to key staff around Modern Slavery, with a dedicated Modern Slavery training and education programme developed that will be rolled out across all of our business and incorporated into induction programmes for all new employees.

In addition, our local policies cover business ethics and codes of conduct as above, and links to our global business ethics incident reporting and local Australian whistleblower speak up line are publicly accessible through the Roche Australia website.

c) Supplier Relationship Management

A dedicated Supplier Relationship Management framework is in operation that provides a direct conduit for supplier engagement and discussion around Modern Slavery in the supply chain. Roche already has an established Supplier Code of Conduct which suppliers are expected to adhere to and this is overseen directly or through ongoing monitoring. Expectations are clearly set through the supplier onboarding process and refreshed at least annually through the relationship management framework.

d) Remediation Processes

Roche does not outsource accountability for compliance to its business partners.

The emphasis in its communications to its suppliers is that inaction and/or prevarication by them will be treated seriously, but that it is willing to work with them to fight Modern Slavery together and remediate any harm done (subject to its obligations to report crimes to the appropriate authorities).

Suppliers have been encouraged to raise any issues or concerns with Roche and Roche has made it clear that it is prepared to agree corrective action plans with them and support them in the implementation of those plans.

As noted above, no remediable issues relating to Modern Slavery were uncovered by our activities during the reporting period

Roche adopts a continuous improvement approach to maintain and enhance the execution and effectiveness of operational processes and procedures.

A risk management framework is maintained that includes a dedicated Modern Slavery Risk Register. This framework, along with the register, is subject to independent review at least annually, or where there is a significant event or change in operations or legislation.

Roche’s full Modern Slavery Statement is available on theWe are committed to constantly improving our procedures so that your personal information is treated appropriately. If you have any questions or would like to know more about our Modern Slavery management practices, please contact Roche by one of the following means:

By mail to:
Roche Products Pty Limited
Level 8, 30-34 Hickson Road
Sydney NSW 2000

Or contact us

By mail to:
Roche Diagnostics Australia Pty Limited
2 Julius Avenue
North Ryde NSW 2113

Or contact us

By mail to:
Roche Diabetes Care Australia Pty Limited
2 Julius Avenue
North Ryde NSW 211

Or contact us

Roche Products Pty Limited ABN 70 000 132 865 | Roche Diagnostics Australia Pty Limited ABN 29 003 001 205 | Roche Diabetes Care Australia Pty Limited ABN 69 602 140 278. This website may contain information about products that are not registered for use in your country of residence and may not comply with applicable laws or regulations in that country. We do not take any responsibility for accessing such information in those circumstances. To report a suspected side effect or product complaint associated with the use of a Roche product, visitor contact Roche Patient Safety atRoche acknowledges the Traditional Owners of Country throughout Australia. We pay our respects to Elders past and present.

ContactLocationslinkedinfacebooktwitterinstagramyoutubeAbout RochePharma solutionsDiagnostic solutionsRoche careersMediaPrivacy policyTerms of use